Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2713040 | 1.00 | PIK3CA (0.47) | PIK3CAPIK3CDROCK2LIMK1LIMK2 | |
| SCHEMBL2713678 | 1.00 | PIK3CA (0.47) | PIK3CAPIK3CDROCK2LIMK1LIMK2 | |
| SCHEMBL2711253 | 0.93 | PIK3CA (0.42) | PIK3CAPIK3CD | |
| SCHEMBL2711899 | 0.93 | PIK3CA (0.42) | PIK3CAPIK3CD | |
| SCHEMBL2712574 | 0.93 | PIK3CA (0.42) | PIK3CAPIK3CD | |
| SCHEMBL3778752 | 0.91 | PIK3CA (0.47) | PIK3CAPIK3CD | |
| SCHEMBL3777815 | 0.91 | PIK3CA (0.47) | PIK3CAPIK3CD | |
| SCHEMBL3777817 | 0.91 | PIK3CA (0.47) | PIK3CAPIK3CD | |
| SCHEMBL3775860 | 0.89 | PIK3CA (0.48) | PIK3CAPIK3CD | |
| SCHEMBL3784844 | 0.89 | PIK3CA (0.48) | PIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 29/4885PIK3CD 14/4885ROCK2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.